Correction: HMGB1-RAGE axis makes no contribution to cardiac remodeling induced by pressure-overload (PLoS ONE (2016) 11:6 (e0158514) DOI: 10.1371/journal.pone.0158514);HMGB1-RAGE axis makes no contribution to cardiac remodeling induced by pressure-overload

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Lin, Hairuo ^a   Shen, Liang ^a,b   Zhang, Xiajun ^a   Xie, Jiahe ^a   Hao, Huixin ^a   Zhang, Yingxue ^a   Chen, Zhenhuan ^a   Yamamoto, Hiroshi ^c   Liao, Wangjun ^a   Bin, Jianping ^a   Cao, Shiping ^a   Huang, Xiaobo ^a   Liao, Yulin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b JIAXING UNIVERSITY   (China)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; AGER PROTEIN, MOUSE; HMGB1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; APOPTOSIS; ARTICLE; BODY WEIGHT; CARDIAC MUSCLE CELL; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOUSE; MTT ASSAY; NEWBORN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; TUNEL ASSAY; UPREGULATION; VASCULAR REMODELING; WILD TYPE MOUSE; ANIMAL; AORTA; CARDIAC MUSCLE; CARDIOMEGALY; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DNA DAMAGE; HOMOZYGOTE; METABOLISM; ORGAN SIZE; PATHOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; AORTA; APOPTOSIS; CARDIOMEGALY; CELL SURVIVAL; CELLS, CULTURED; DNA DAMAGE; HMGB1 PROTEIN; HOMOZYGOTE; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN SIZE; RATS; TOLL-LIKE RECEPTOR 4;

EID: 84977527414     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0167872     Document Type: Erratum

References (41)

1. Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem. 1989; 185: 303-310. PMID: 2583185
2. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004; 255: 332-343. PMID: 14871457
3. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. Mol Aspects Med. 2014; 40: 1-116. doi: 10.1016/j.mam.2014.05.001 PMID: 25010388
4. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, et al. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol. 2007; 81: 741-747. PMID: 17135572
5. Zhang X, Wheeler D, Tang Y, Guo L, Shapiro RA, Ribar TJ, et al. Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J Immunol. 2008; 181: 5015-5023. PMID: 18802105
6. Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, Susarla S, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol. 2004; 76: 994-1001. PMID: 15331624
7. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011; 12: 695-708. doi: 10.1038/ni.2065 PMID: 21772278
8. Kamo N, Ke B, Ghaffari AA, Shen XD, Busuttil RW, Cheng G, et al. ASC/caspase-1/IL-1beta signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology. 2013; 58: 351-362. doi: 10.1002/hep.26320 PMID: 23408710
9. Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci. 2011; 36: 625-632. doi: 10.1016/j.tibs.2011.08.008 PMID: 22019011
10. Herzog C, Lorenz A, Gillmann HJ, Chowdhury A, Larmann J, Harendza T, et al. Thrombomodulin's lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling. Cardiovasc Res. 2014; 101: 400-410. doi: 10.1093/cvr/cvt275 PMID: 24323314
11. Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis. 2015; 20: 196-209. doi: 10.1007/s10495-014-1073-1 PMID: 25563856
12. Braunwald E. Heart failure. JACC Heart Fail. 2013; 1: 1-20. doi: 10.1016/j.jchf.2012.10.002 PMID: 24621794
13. Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, et al. Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. Cell Death Differ. 2013; 20: 765-773. doi: 10.1038/cdd.2013.8 PMID: 23412345
14. Xu H, Yao Y, Su Z, Yang Y, Kao R, Martin CM, et al. Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am J Physiol Heart Circ Physiol. 2011; 300: H913-921. doi: 10.1152/ajpheart.00703.2010 PMID: 21186276
15. Meng Q, Zhao J, Liu H, Zhou G, Zhang W, Xu X, et al. HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma. Tumour Biol. 2014; 35: 12265-12274. doi: 10.1007/s13277-014-2535-3 PMID: 25168370
16. Xu X, Zhu H, Wang T, Sun Y, Ni P, Liu Y, et al. Exogenous high-mobility group box 1 inhibits apoptosis and promotes the proliferation of lewis cells via RAGE/TLR4-dependent signal pathways. Scand J Immunol. 2014; 79: 386-394. doi: 10.1111/sji.12174 PMID: 24673192
17. Funayama A, Shishido T, Netsu S, Narumi T, Kadowaki S, Takahashi H, et al. Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res. 2013; 99: 657-664. doi: 10.1093/cvr/cvt128 PMID: 23708738
18. Nakamura Y, Suzuki S, Shimizu T, Miyata M, Shishido T, Ikeda K, et al. High Mobility Group Box 1 Promotes Angiogenesis from Bone Marrow-derived Endothelial Progenitor Cells after Myocardial Infarction. J Atheroscler Thromb. 2015; 22: 570-581. doi: 10.5551/jat.27235 PMID: 25735431
19. Chen WY, Hong J, Gannon J, Kakkar R, Lee RT. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc Natl Acad Sci U S A. 2015; 112: 7249-7254. doi: 10.1073/pnas.1424236112 PMID: 25941360
20. Yoshida T, Friehs I, Mummidi S, del Nido PJ, Addulnour-Nakhoul S, Delafontaine P, et al. Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-alpha-induced cardiomyocyte death. J Mol Cell Cardiol. 2014; 75: 141-151. doi: 10.1016/j.yjmcc.2014.07.007 PMID: 25108227
21. Su FF, Shi MQ, Guo WG, Liu XT, Wang HT, Lu ZF, et al. High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediators Inflamm. 2012; 2012: 805149. doi: 10.1155/2012/805149 PMID: 22778498
22. Jia Z, Xue R, Liu G, Li L, Yang J, Pi G, et al. HMGB1 Is Involved in the Protective Effect of the PPAR alpha Agonist Fenofibrate against Cardiac Hypertrophy. 2014; 2014: 541394.
23. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007; 117: 2847-2859. PMID: 17853945
24. Chen HM, Liou SF, Hsu JH, Chen TJ, Cheng TL, Chiu CC, et al. Baicalein inhibits HMGB1 release and MMP-2/-9 expression in lipopolysaccharide-induced cardiac hypertrophy. Am J Chin Med. 2014; 42: 785-797. doi: 10.1142/S0192415X14500505 PMID: 25004875
25. Bangert A, Andrassy M, Muller AM, Bockstahler M, Fischer A, Volz CH, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci U S A. 2016; 113: E155-164. doi: 10.1073/pnas.1522288113 PMID: 26715748
26. Jhun J, Lee S, Kim H, Her YM, Byun JK, Kim EK, et al. HMGB1/RAGE induces IL-17 expression to exaggerate inflammation in peripheral blood cells of hepatitis B patients. J Transl Med. 2015; 13: 310. doi: 10.1186/s12967-015-0663-1 PMID: 26391982
27. Wei X, Wu B, Zhao J, Zeng Z, Xuan W, Cao S, et al. Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9. Circulation. 2015; 131: 1506-1517; discussion 1517. doi: 10.1161/CIRCULATIONAHA.114.013789 PMID: 25820336
28. Zeng Z, Shen L, Li X, Luo T, Wei X, Zhang J, et al. Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin Sci (Lond). 2014; 127: 435-448.
29. Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, et al. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res. 2011; 92: 385-393. doi: 10.1093/cvr/cvr221 PMID: 21840883
30. Li X, Zeng Z, Li Q, Xu Q, Xie J, Hao H, et al. Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget. 2015; 6: 18829-18844. PMID: 26299920
31. Luo T, Chen B, Zhao Z, He N, Zeng Z, Wu B, et al. Histamine H2 receptor activation exacerbates myocardial schemia/reperfusion injury by disturbing mitochondrial and endothelial function. Basic Res Cardiol. 2013; 108: 342-356. doi: 10.1007/s00395-013-0342-4 PMID: 23467745
32. Zhang L, Liu M, Jiang H, Yu Y, Yu P, Tong R, et al. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure. J Cell Mol Med. 2015.
33. Ehrentraut H, Weber C, Ehrentraut S, Schwederski M, Boehm O, Knuefermann P, et al. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur J Heart Fail. 2011; 13: 602-610. doi: 10.1093/eurjhf/hfr035 PMID: 21613426
34. Jiang DS, Zhang XF, Gao L, Zong J, Zhou H, Liu Y, et al. Signal regulatory protein-alpha protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling. Hypertension. 2014; 63: 96-104. doi: 10.1161/HYPERTENSIONAHA.113.01506 PMID: 24101669
35. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res. 2005; 68: 224-234. PMID: 15967420
36. Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, et al. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner. Arterioscler Thromb Vasc Biol. 2014; 34: 1399-1411. doi: 10.1161/ATVBAHA.114.303508 PMID: 24855059
37. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, et al. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol. 2002; 282: H1703-1708. PMID: 11959634
38. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2014; 19: 681-694. doi: 10.1007/s10741-013-9405-8 PMID: 24005868
39. Ding HS, Yang J, Chen P, Yang J, Bo SQ, Ding JW, et al. The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis. Gene. 2013; 527: 389-393. doi: 10.1016/j.gene.2013.05.041 PMID: 23727604
40. Wang WK, Lu QH, Zhang JN, Wang B, Liu XJ, An FS, et al. HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway. J Cell Mol Med. 2014; 18: 2311-2320. doi: 10.1111/jcmm.12399 PMID: 25210949
41. Narumi T, Shishido T, Otaki Y, Kadowaki S, Honda Y, Funayama A, et al. High-mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis. J Mol Cell Cardiol. 2015; 82: 1-12. doi: 10.1016/j.yjmcc.2015.02.018 PMID: 25736854